Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.42 |
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14248067 | 1.00 | CTSK (0.42) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL14318518 | 0.86 | SMN1; SMN2 (0.42) | CTSKCTSSCTSL | |
| SCHEMBL15005809 | 0.85 | CTSK (0.37) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL24067299 | 0.82 | CTSK (0.55) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL17627333 | 0.82 | CTSK (0.47) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL17498476 | 0.82 | CTSK (0.47) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL22359140 | 0.81 | CTSK (0.46) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL12658511 | 0.81 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL21419058 | 0.79 | CTSK (0.52) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL28000286 | 0.79 | CTSK (0.52) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721053-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2721053-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20130142754-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-06-06 | — | — | US | disclosed |
| WO-2012173983-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142754-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | CTSK 945/4885CTSS 1082/4885MEN1 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.